Involvement of Immune Cells Derived From the Intestine in Sjogren's Syndrome (SINGOU)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03841318|
Recruitment Status : Recruiting
First Posted : February 15, 2019
Last Update Posted : August 4, 2020
|Condition or disease||Intervention/treatment||Phase|
|Sjogren's Syndrome||Biological: blood sample Biological: biopsy of the labial salivary gland||Not Applicable|
Autoimmune diseases are characterized by a loss of tolerance of the immune system for self-antigens. One of the feature of autoimmune diseases is the infiltration of lymphoid cells in the tissues damaged by the disease (i.e. kidney in systemic lupus erythematous or brain in multiple sclerosis). However, the origins and properties of the immune cells infiltrating these target tissues are largely unknown.
Studies in mouse models have shown that the composition of the gut microbiota can modify the susceptibility to autoimmune diseases. These studies demonstrated that the microbiota composition can alter the pathogenic properties of T cells in the gut but also in the target tissues. For instance, in the experimental autoimmune encephalomyelitis model, the composition of the gut microbiota has been shown to modulate the susceptibility to the disease and the properties of the pathogenic CD4 T cells in the gut but also in the central nervous system. In human an alteration in the composition of the gut microbiota is observed in numerous autoimmune diseases, including Sjogren's syndrome, suggesting that perturbation of the gut microbiota might be linked to the pathogenicity of immune cells in the target organs. However, the mechanisms by which the microbiota impacts the pathogenicity of immune cells in the target organs is unknown. It is proposed that gut immune cells directly exposed to the microbiota compounds could migrate to the target organs and participate to the buildup of tissue damages. This hypothesis is supported by studies in mouse models showing the migration of gut CD4 T cells in the inflamed kidney (glomerulonephritis model) or in the systemic lymphoid organs (rheumatoid arthritis model). The preliminary data support this hypothesis as the investigators have shown that gut-derived CD4 T cells display pathogenic properties in human autoimmune diseases. To determine whether and how the gut-derived immune cells are involved in the pathogenesis of autoimmune disease, the investigators propose to study the origin and properties of immune cells infiltrated in target tissues in autoimmune diseases.
Sjogren's syndrome is a systemic autoimmune disease in which exocrine gland in particular lacrimal and salivary glands are affected. One of the hallmark of the disease is the infiltration of lymphoid cells in the exocrine glands of the patients. Indeed, the presence of lymphoid infiltrate in the minor labial salivary gland of the patients is one of the most important diagnostic tool for Sjogren's syndrome. The investigation of lymphoid infiltrates requires to perform a biopsy of the labial salivary gland. The investigators propose here to take advantage of this minimally invasive procedure to study the properties of the lymphoid cells present in the minor salivary glands of Sjogren's patients.
The study will recruit 200 patients followed in Bordeaux University Hospital in which a salivary gland biopsy is performed for a clinical suspicion of Sjogren's syndrome. Blood and a biopsy of the minor salivary gland of the lip will be collected during a scheduled visit to study the properties of infiltrated immune cells. Clinical and biological disease activity, treatment and outcomes will be studied in correlation with the properties of infiltrated immune cells. No extra visit will be needed and the biopsy of the minor salivary gland of the lip and the blood samples will be collected at the same times as those collected for clinical purposes.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Involvement of Immune Cells Derived From the Intestine in Sjogren's Syndrome|
|Actual Study Start Date :||August 3, 2020|
|Estimated Primary Completion Date :||August 2023|
|Estimated Study Completion Date :||August 2023|
|Experimental: Sjogren's Syndrome||
Biological: blood sample
36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Biological: biopsy of the labial salivary gland
Part of the biopsy of the labial salivary gland
- Quantification of the immune cells infiltrated in the minor salivary glands of Sjogren's patients. [ Time Frame: At baseline (Day 0) ]
- Quantification of disease activity scores for Sjogren's patients evalued by EULAR Sjögren Syndrome Disease Activity Index [ Time Frame: At baseline (Day 0) ]EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) : between 0 and 123, in which higher values indicate higher severity
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03841318
|Contact: Pierre DUFFAU, Prof||(0)5 56 79 58 28 ext +email@example.com|
|Contact: Nathalie SCHMITT, PhD||(0)7 87 99 14 70 ext +firstname.lastname@example.org|
|CHU de Bordeaux - Service de médecine interne||Recruiting|
|Contact: Pierre DUFFAU, Prof (0)5 56 79 58 28 ext +33 email@example.com|
|Contact: Nathalie SCHMITT, PhD (0)7 87 99 14 70 ext +33 firstname.lastname@example.org|
|Principal Investigator: Pierre DUFFAU, Prof|
|Sub-Investigator: Estibaliz LAZARO, Prof|
|Principal Investigator:||Pierre DUFFAU, Prof||CHU - Bordeaux|